ViGenCell바이젠셀
308080 · KOSDAQ · ₩308080 · 바이젠셀
₩5,070 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 4.8% | 48.8% | 4.3% | — | — | — |
| Operating margin | −1,533.4% | −75,453.1% | −5,487.2% | — | — | — |
| Net margin | −1,438.4% | −71,986.4% | −5,039.8% | — | — | — |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +3,966.2% | −91.9% | — | — | — | — |
| Operating income growth | +17.4% | −11.8% | +23.4% | −9.9% | −38.4% | — |
| Net income growth | +18.8% | −16.1% | +21.4% | −2.8% | −56.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −32.1% | −32.1% | −21.7% | −22.2% | −17.9% | −10.6% |
| Return on assets | −25.5% | −26.8% | −18.9% | −19.8% | −16.1% | −9.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 28.0% | 24.1% | 16.1% | 13.4% | 10.9% | 11.5% |
| Net debt to equity | −57.1% | −59.4% | −65.1% | −64.4% | −1.0% | −22.0% |
| Current ratio | 1,526.8% | 2,003.5% | 573.3% | 642.5% | 836.8% | 654.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: ViGenCell / 바이젠셀 / 308080 / KRX:308080
Source: KRX statistical information